Skip to main content

Novus Biologicals products are now on bio-techne.com

Better as one

Recombinant SARS-CoV-2 NSP14 His-tag Protein, CF

Bio-Techne includes R&D Systems | Catalog # 10667-CV

Catalog #
Availability
Size / Price
Qty
Loading...
10667-CV-050

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Product Specifications

Source

E. coli-derived sars-cov-2 NSP14 protein
Ala1-Gln527
with a C-terminal 6-His tag

Purity

>85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<1.0 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Ala1

Predicted Molecular Mass

61 kDa

SDS-PAGE

53-62 kDa, under reducing conditions

Formulation, Preparation and Storage

10667-CV
Formulation Supplied as a 0.2 μm filtered solution in Tris, NaCl, TCEP and Glycerol.
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 6 months from date of receipt, -20 to -70 °C as supplied.
  • 3 months, -20 to -70 °C under sterile conditions after opening.

Background: NSP14

Non-structural protein 14 (NSP14) is one of several functional proteins released by ORF1a-encoded protease cleavage of the pp1a and pp1ab replicase polyproteins expressed from the coronavirus (CoV) genome (1). The NSPs are involved in the replication and transcription of the viral RNA and not incorporated within the virion particles. Coronaviruses include various highly pathogenic strains such as SARS-CoV, MERS-CoV and SARS-CoV2 that have had significant impact on humans in addition to strains that have negatively impacted livestock. NSP14 is a bifunctional 527 amino acid enzyme. It contains a noncanonical methyltransferase (MTase) domain in the C‑terminal portion of the protein that methylates guanosine at the N7 position using S-adenosyl methionine (SAM) as a methyl donor to generate the intermediate cap-O structure of the 5' mRNA cap (2). The viral RNA cap structure protects the viral RNA from degradation, promotes mRNA translation, and prevents recognition by innate immune mechanisms (3). As the MTase active site fold is unique from cellular MTases (4), NSP14 presents an attractive antiviral target. The C‑terminal domain is connected via a hinge region to an N‑terminal exonuclease domain composed of three highly conserved motifs (5). The 3' to 5' exonuclease function of the N-terminal domain is responsible for the proofreading and high-fidelity replication observed in coronaviruses compared to other RNA viruses (6-8). NSP14 has been shown to form a complex with NSP10; the association with NSP10 was shown to stimulate exonuclease catalytic activity more than 35-fold and is required for the high replication fidelity (9,10). Exonuclease function makes polymerase inhibition via nucleos(t)ide analog (NA) development more challenging because it confers resistance via its error-correcting mechanism for NA incorporated into RNA (6,9). NSP14 exonuclease domain mutation studies showed it is absolutely required for viability and replication of SARSCoV2 (11) suggesting exonuclease activity may serve a more extensive role in replication than proof-reading (11,12). NSP14 was suggested to be involved in mediating recombination frequency and junction site selection in coronavirus (13). Both for the role it plays in resistance to polymerase inhibition and based on absolute requirement for viability, NSP14 is an appealing protein to target for therapeutic and vaccine development (8,11,13,14). 

References

  1. Snijder, E.J. et al. (2016) Adv. Virus Res. 96:59.
  2. Jin, X. et al. (2013) Virus Res. 176:45.
  3. Decroly, E. et al. (2011) PLoS Pathog. 7:e1002059.
  4. Chen, Y. et al. (2009) Proc. Natl. Acad. Sci. USA 106:3484.
  5. Ogando, N.S. et al. (2019) Front. Microbiol. 10:1813.
  6. Minskaia, E. et al. (2006) Proc. Natl. Acad. Sci. USA 103:5108.
  7. Eckerle, L. et al. (2007) J. Virol. 81:12135.
  8. Smith, E.C. et al. (2013) PLoS Pathog. 9:e1003565.
  9. Bouvet, M. et al. (2012) Proc. Natl. Acad. Sci. 109:9372.
  10. Smith, E.C. et al. (2015) J. Virol. 89:6418.
  11. Ogando, N.S. et al. (2020) J. Virol. 94:e01246.
  12. Baddock, H.T. et al. (2020) (pre-print)
  13. Gribble, J. et al. (2020) bioRxiv (pre-print) 
  14. Shannon, A. et al. (2020) Antiviral Res. 178:104793.

Long Name

Non-Structural Protein 14

UniProt

Additional NSP14 Products

Product Documents for Recombinant SARS-CoV-2 NSP14 His-tag Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant SARS-CoV-2 NSP14 His-tag Protein, CF

For research use only

Customer Reviews for Recombinant SARS-CoV-2 NSP14 His-tag Protein, CF (1)

4 out of 5
1 customer rating
5 stars
0%
4 stars
100%
3 stars
0%
2 stars
0%
1 star
0%

Customer Images


Showing  1 - 1 of 1 review Showing All
Filter By:
  • Recombinant SARS-CoV-2 NSP14 His-tag Protein, CF
    Name: Anonymous
    Application: In vitro bioactivity in cell culture
    Verified Customer | Posted 06/20/2022
    Recombinant SARS-CoV-2 NSP14 His-tag Protein, CF 10667-CV

There are no reviews that match your criteria.

Showing  1 - 1 of 1 review Showing All